AVTX NASDAQ
Avalo Therapeutics, Inc.
1W: -45.4%
1M: -55.2%
3M: -64.5%
YTD: -60.3%
1Y: -61.6%
3Y: -77.1%
5Y: -99.9%
$6.75
-0.02 (-0.30%)
Pre-Market: $6.73 (-0.02, -0.30%)
Weekly Expected Move ±20.7%
$4
$5
$7
$8
$10
Credit Risk of going bust: lower than 74% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Avalo Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242K against a stock market value of $362.0M.
Distance to default 8.27 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $121K (short-term plus half of long-term), stock volatility 92.2%; Altman Z'' 11.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Avalo Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242K against a stock market value of $362.0M.
Distance to default 8.27 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $121K (short-term plus half of long-term), stock volatility 92.2%; Altman Z'' 11.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
24 relationships24
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-03-31
Earliest Filing
2025-06-05
Latest Filing
partner: 11
licensee: 5
investor: 4
acquirer: 2
target: 1
customer: 1
Counterparties (Filed by AVTX)
24 relationshipsCompanies named in AVTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Oppenheimer & Co. Inc. | OPY | partner | Former sales agent for the offering of up to $50.0 million in common stock, agreement terminated | 2025-06-05 | View |
| AlmataBio, Inc. | — | target | Target company in the merger agreement with Avalo Therapeutics, Inc. | 2024-03-28 | View |
| AUG Therapeutics, LLC | — | acquirer | Acquired rights and assets relating to AVTX-801, AVTX-802, and AVTX-803 from Avalo Therapeutics, Inc. | 2023-10-31 | View |
| Nasdaq Stock Market LLC | NDAQ | partner | Exchange listing authority that notified Company of delisting | 2023-09-26 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Sales agent for the Company's common stock offering | 2023-09-26 | View |
| AUG Therapeutics, LLC | — | acquirer | AUG Therapeutics, LLC entered into an Asset Purchase Agreement to acquire rights to the 800 Series compounds from Avalo | 2023-09-12 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Entered into an amended sales agreement to sell up to $50 million of the Company's common stock. | 2023-08-07 | View |
| Venrock Healthcare Capital Partners EG, L.P. | — | investor | Received pre-funded warrants in exchange for common stock | 2023-06-02 | View |
| Venrock Healthcare Capital Partners III, L.P. | — | investor | Received pre-funded warrants in exchange for common stock | 2023-06-02 | View |
| VHCP Co-Investment Holdings III, LLC | — | investor | Received pre-funded warrants in exchange for common stock | 2023-06-02 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Sales agent for the Company's at-the-market offering of common stock. | 2023-05-04 | View |
| ES Therapeutics, LLC | — | customer | Purchased rights to milestone payments and future royalties from Avalo Therapeutics, Inc. | 2022-11-14 | View |
| Armistice Capital Master Fund Ltd. | — | investor | Significant stockholder and affiliate of ES Therapeutics, LLC; party to Assignment of License Agreement. | 2022-11-14 | View |
| Janssen Pharmaceuticals, Inc. | — | partner | Original counterparty to Asset Purchase Agreement regarding AVTX-501 whose rights were sold by Avalo Therapeutics, Inc. | 2022-11-14 | View |
| Apollo AP43 Limited | — | partner | Original counterparty to License Agreement regarding AVTX-007 whose rights were sold by Avalo Therapeutics, Inc. | 2022-11-14 | View |
| Apollo AP43 Limited | — | licensee | Granted exclusive license to AVTX-007 and novated MedImmune license agreement | 2022-08-01 | View |
| Apollo Therapeutics Group Limited | — | partner | Parent company of Apollo AP43 Limited | 2022-08-01 | View |
| MedImmune Limited | — | licensee | Original licensor whose agreement was novated to Apollo | 2022-08-01 | View |
| Jefferies LLC | JEF | partner | Representative of underwriters in the public offering of common stock | 2021-09-15 | View |
| RBC Capital Markets, LLC | — | partner | Representative of underwriters in the public offering of common stock | 2021-09-15 | View |
| Sanford Burnham Prebys Medical Discovery Institute | — | licensee | Cerecor entered into an exclusive patent license agreement to obtain rights to the CERC-008 immune checkpoint program. | 2021-06-23 | View |
| Alto Neuroscience, Inc. | ANRO | licensee | Cerecor outlicensed all rights in its non-core asset CERC-301 to Alto. | 2021-06-23 | View |
| ES Therapeutics, LLC | — | licensee | Cerecor assigned all rights under an in-license covering asset CERC-406 to ES. | 2021-06-23 | View |
| Kyowa Kirin Co., Ltd. | — | partner | Entered into a License Agreement for exclusive worldwide rights to develop, manufacture, and commercialize CERC-002. | 2021-03-31 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-23 | Officer/Director Change | View | |
| 2026-06-16 | Other Events; Exhibits | View | |
| 2026-06-12 | Unregistered Equity Sales; Officer/Director Change; Bylaws Amendment; Exhibits | View | |
| 2026-06-08 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-05-07 | Material Agreement; Earnings Release; Regulation FD; Exhibits | Agreement | View |
| 2026-05-05 | Other Events; Exhibits | View | |
| 2026-04-28 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-03-27 | Officer/Director Change | View | |
| 2026-03-23 | Earnings Release; Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Other Events | View | |
| 2025-12-02 | Other Events | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-29 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-01 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-09-22 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-20 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR